Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen and Nasdaq Exchange Resolve Dispute

NEW YORK, Jan.24, (GenomeWeb News) - The "E" appended to Ciphergen's ticker symbol will be gone tomorrow as the company has been informed by Nasdaq National Market officials that it has "evidenced compliance" in listing requirements, Ciphergen said today.


As GenomeWeb News reported last week, the Nasdaq questioned Ciphergen's July 2005 stock sale to Quest, suggesting that the deal "constituted a change of control which required shareholder approval" because the deal could result in Quest's owning more than 20 percent of the total outstanding shares. Ciphergen replied that Quest would not own more than 19.9 percent of Ciphergen.


Ciphergen declined to comment on the resolution of the dispute.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.